This inventor holds 126 USPTO granted patents and 48 published patent applications, plus 7 CIPO patents and 30 EPO patents, primarily in Deuterated Compounds (CPC class C07B2200-05). Top assignees: Concert Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., Vertex Pharmaceuticals (Europe) Limited. Active years: 1993-2025.
Inventors with similar research interests:
Location History:
- Cambridge, MA (US) (1993 - 2001)
- Berverly, MA (US) (2005)
- Beverly, MA (US) (2003 - 2009)
- Arlington, MA (US) (1996 - 2012)
- San Diego, CA (US) (2003 - 2013)
- Lexington, MA (US) (2009 - 2024)
Company Filing History:
74 out of 136 
43 out of 1,167 
3 out of 5 
Years Active: 1993-2025
Areas of Expertise:
Title: Roger D Tung: Innovator Extraordinaire in Pharmaceuticals
Introduction:
Roger D Tung, a seasoned inventor hailing from Lexington, MA, has made significant contributions to the field of pharmaceuticals. With a staggering number of 123 patents to his name, Tung's innovative prowess is evident. His latest patents, relating to morphinan compounds and 4-hydroxybutyric acid analogs, showcase his persistent dedication to advancing medical treatments. Let us delve into Tung's remarkable career and notable collaborations.
Latest Patents:
Tung's recent patents highlight his profound impact on the pharmaceutical industry. The first patent focuses on novel morphinan compounds, their derivatives, and their applications in treating diseases and conditions that benefit from a σ-receptor agonist with NMDA antagonist activity. This groundbreaking innovation holds promise for the development of more effective treatments.
The second patent centers around 4-hydroxybutyric acid analogs and their prodrugs, along with pharmaceutical compositions for treating narcolepsy, fibromyalgia, and improving nocturnal sleep. Tung's research in this area demonstrates his dedication to addressing sleep-related disorders and improving the quality of life for affected individuals.
Career Highlights:
Throughout his career, Tung has made significant contributions to renowned pharmaceutical companies. He has worked at Concert Pharmaceuticals, Inc., focusing on pioneering advancements in drug development. Additionally, Tung's expertise has been instrumental in driving progress at Vertex Pharmaceuticals, Inc. His contributions to these organizations have undoubtedly played a key role in their success and further solidify his standing as an esteemed inventor.
Collaborations:
Tung's brilliance extends beyond his individual achievements. Collaborating with like-minded individuals has enhanced his ability to produce groundbreaking inventions. Notably, Tung has worked closely with accomplished professionals such as Scott L Harbeson and Govinda Rao Bhisetti. These fruitful collaborations have undoubtedly contributed to the advancements in pharmaceutical research and development.
Conclusion:
Roger D Tung's impressive array of patents and contributions to the pharmaceutical field solidify his status as an innovator extraordinaire. His latest patents in morphinan compounds and 4-hydroxybutyric acid analogs demonstrate his dedication to improving treatment options for various diseases and disorders. Through his impactful career and collaborations with talented colleagues, Tung continues to shape the future of pharmaceutical innovation.